Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Apr 10:61:89-91.
doi: 10.1016/j.jdcr.2025.03.026. eCollection 2025 Jul.

A case of concurrent exacerbation of manifestations and asthma after the initiation of nemolizumab treatment for atopic dermatitis

Michie Katsuta  1 , Ayaka Osawa  1 , Yozo Ishiuji  1 , Satomi Fujii  1 , Masahiro Kanbe  1 , Akihiko Asahina  1 , Yoshimasa Nobeyama  1
Affiliations
Case Reports

A case of concurrent exacerbation of manifestations and asthma after the initiation of nemolizumab treatment for atopic dermatitis

Michie Katsuta et al. JAAD Case Rep. .
No abstract available

Keywords: IL-31; Th2; asthma; atopic dermatitis; itch; nemolizumab.

PubMed Disclaimer

Conflict of interest statement

Drs Katsuta, Nobeyama, and Asahina received research funding and honorariums from Maruho as speakers. Dr Ishiuji received an honorarium as a speaker from Maruho, Sanofi, Abbvie, Pfizer, Eli Lilly, and Otsuka. The other authors have no conflicts of interest to declare.

Figures

Fig 1
Fig 1
A, B, Clinical presentation at the start of nemolizumab treatment; C, D, at 4 weeks; E, F, at 8 weeks; and G, H, at 12 weeks.
Fig 2
Fig 2
A, Histopathologic findings showing liquefactive degeneration of the dermis and infiltration of eosinophils; B, immunohistochemistry CD4+ cells; C, immunohistochemistry CD8+ cells.
See this image and copyright information in PMC

References

    1. Kabashima K., Matsumura T., Komazaki H., Kawashima M., Nemolizumab-JP01 Study Group Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med. 2020;383(2):141–150. doi: 10.1056/NEJMoa1917006. - DOI - PubMed
    1. Hanifin J.M., Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol. 1980;60(2):44–47. doi: 10.2340/00015555924447. - DOI
    1. Nathan R.A., Sorkness C.A., Kosinski M., et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113(1):59–65. doi: 10.1016/j.jaci.2003.09.008. - DOI - PubMed
    1. Fassett M.S., Braz J.M., Castellanos C.A., et al. IL-31-dependent neurogenic inflammation restrains cutaneous type 2 immune response in allergic dermatitis. Sci Immunol. 2023;8(88) doi: 10.1126/sciimmunol.abi6887. - DOI - PMC - PubMed
    1. Lai T., Wu D., Li W., et al. Interleukin-31 expression and relation to disease severity in human asthma. Sci Rep. 2016;6 doi: 10.1038/srep22835. - DOI - PMC - PubMed

Publication types

LinkOut - more resources